Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLT CVE:CZX TSE:FCR CVE:PNN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$5.96-3.7%$6.24$5.20▼$15.60$11.44M0.8911,791 shs54,117 shsCZXCanada Zinc MetalsC$0.31+∞C$0.31C$0.22▼C$0.39C$51.69MN/A238,645 shs118,500 shsFCRFirst Capital RealtyC$0.00C$18.60▼C$22.79N/AN/A468,009 shs3.04 million shsPNNPambili Natural ResourcesC$0.06+10.0%C$0.04C$0.02▼C$0.08C$3.01M-2.4324,117 shs18,550 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics0.00%+1.49%+1.48%-16.35%-58.69%CZXCanada Zinc Metals0.00%0.00%0.00%0.00%0.00%FCRFirst Capital Realty0.00%0.00%0.00%0.00%0.00%PNNPambili Natural Resources0.00%0.00%+57.14%+57.14%-21.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBOLTBolt Biotherapeutics3.0571 of 5 stars3.22.00.00.02.73.31.3CZXCanada Zinc MetalsN/AN/AN/AN/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/AN/AN/AN/AN/AN/APNNPambili Natural ResourcesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.33Hold$50.00738.93% UpsideCZXCanada Zinc Metals 0.00N/AN/AN/AFCRFirst Capital Realty 4.00Strong BuyN/AN/APNNPambili Natural Resources 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PNN, BOLT, CZX, and FCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/13/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$25.00 ➝ $20.00(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.49N/AN/A$29.89 per share0.20CZXCanada Zinc MetalsN/AN/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/AN/AN/AN/APNNPambili Natural ResourcesC$92.47K32.59C$0.02 per share2.50C($0.01) per share-6.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$63.12M-$33.40N/AN/AN/AN/A-94.51%-59.07%8/12/2025 (Estimated)CZXCanada Zinc MetalsN/AN/A0.00∞N/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/A0.00N/AN/AN/AN/AN/AN/APNNPambili Natural Resources-C$2.61M-C$0.05N/A∞N/A-2,818.86%107.16%-192.70%N/ALatest PNN, BOLT, CZX, and FCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025BOLTBolt Biotherapeutics-$6.80-$5.80+$1.00-$0.29$0.77 million$1.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/ACZXCanada Zinc MetalsN/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/AN/AN/APNNPambili Natural ResourcesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.483.133.13CZXCanada Zinc MetalsN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/APNNPambili Natural Resources-375.100.070.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%CZXCanada Zinc MetalsN/AFCRFirst Capital RealtyN/APNNPambili Natural ResourcesN/AInsider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics30.90%CZXCanada Zinc MetalsN/AFCRFirst Capital RealtyN/APNNPambili Natural Resources26.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.33 millionNot OptionableCZXCanada Zinc Metals147,000166.73 millionN/ANot OptionableFCRFirst Capital RealtyN/AN/AN/ANot OptionablePNNPambili Natural ResourcesN/A54.80 millionN/ANot OptionablePNN, BOLT, CZX, and FCR HeadlinesRecent News About These CompaniesPambili Natural Resources Seeks to Raise C$1-Mln for Zim VentureJune 26, 2025 | msn.comPambili Natural Resources Reports Encouraging Gold Assay Results From East Adit Cross-CutJune 19, 2025 | juniorminingnetwork.comPambili Natural Resources Provides Update on Development of the East Adit Cross-Cut at GVMJune 11, 2025 | juniorminingnetwork.comPambili Natural Resources: Development of Cross-Cut Into New Gold Target UnderwayMay 30, 2025 | juniorminingnetwork.comLondon Wall Due Diligence: 8.87 g/t Sample Metallurgical Test Results and Identification of Large-Scale Potential Gold SystemMay 15, 2025 | juniorminingnetwork.comPambili Natural Resources Strengthens Board with Appointment of Victor Feng as a DirectorFebruary 27, 2025 | juniorminingnetwork.comPambili Natural Resources Confirms Down-dip Extension of Gold Mineralization at Golden Valley Mine in ZimbabweJanuary 14, 2025 | juniorminingnetwork.comPambili Natural Resources Announces New High Grade Vein at Golden ValleyNovember 25, 2024 | juniorminingnetwork.comPambili Signs Option to Purchase the London Wall Group of Gold MinesNovember 21, 2024 | stockhouse.comPambili Natural Resources Signs Option to Purchase the London Wall Group of Gold MinesNovember 21, 2024 | juniorminingnetwork.comPambili Natural Resources Provides Underground Drilling Update on Zimbabwe's Golden Valley MineNovember 13, 2024 | juniorminingnetwork.comPambili Shifts Focus to Gold Mining in ZimbabweOctober 30, 2024 | markets.businessinsider.comPambili Announces Divestiture of Legacy Oil and Gas AssetsOctober 29, 2024 | theglobeandmail.comPambili Natural Resources Corp.October 18, 2024 | wsj.comApplied Natural Resource Economics—MSOctober 12, 2024 | mtu.eduMPambili Natural Resources: Bringing Golden Valley's Production Plant Back OnlineOctober 4, 2024 | stockhouse.comPambili Natural Resources Commences Underground Drilling at Golden Valley Mine; Program Targeting Near-Term Source of OreSeptember 11, 2024 | juniorminingnetwork.comPambili Announces Appointment of Interim Chief Financial OfficerAugust 17, 2024 | stockhouse.comClosing Bell: Pambili Natural Resources Corp flat on Friday (PNN)August 3, 2024 | theglobeandmail.comClosing Bell: Pambili Natural Resources Corp up on Wednesday (PNN)August 2, 2024 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePNN, BOLT, CZX, and FCR Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$5.96 -0.23 (-3.72%) Closing price 04:00 PM EasternExtended Trading$5.92 -0.04 (-0.69%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Canada Zinc Metals CVE:CZXC$0.31 +0.31 (+∞) As of 05/4/2018Canada Zinc Metals Corp. explores for and evaluates mineral resource properties in Canada. The company primarily explores for zinc-lead-silver base metals deposits. Its flagship property is the Akie property that consists of 46 mineral claims, which cover approximately 116 square kilometers, located in the Paleozoic Selwyn Basin, British Columbia. The company was formerly known as Mantle Resources Inc. and changed its name to Canada Zinc Metals Corp. in September 2008. Canada Zinc Metals Corp. was incorporated in 1988 and is headquartered in Vancouver, Canada.First Capital Realty TSE:FCRPambili Natural Resources CVE:PNNC$0.06 +0.01 (+10.00%) As of 07/3/2025Pambili Natural Resources Corporation engages in the evaluation, acquisition, exploration, and development of oil and gas properties in Canada and Zimbabwe. It operates Happy Valley gold mine in Bulawayo, Zimbabwe. The company was formerly known as Pennine Petroleum Corporation and changed its name to Pambili Natural Resources Corporation in June 2022. Pambili Natural Resources Corporation was incorporated in 2001 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling Hits Market Leaders—Should You Be Worried? MP Materials Stock Booms on New Government Positioning Tilray Shares Blazing: What's Behind the 55% Rally This Month? MarketBeat Week in Review – 07/07 - 07/11 How Texas Roadhouse Is Winning in a Changing Consumer Market Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.